High alkaline phosphatase: what can cause it?

Common reasons for high alkaline phosphatase

An elevated alkaline phosphatase (ALP) result often points toward the liver, bile ducts, or bones. Other explanations include pregnancy, growth, and certain medications. A gamma-glutamyl transferase (GGT) test can help distinguish a liver or bile-duct source from a bone source. The result needs context: ALP alone does not identify the cause. Source

Cause	Examples	Possible ALP pattern	GGT/ALT pattern
Blocked bile duct	Gallstones, tumors, or strictures	Can rise severalfold; no single diagnostic threshold	GGT often elevated
Hepatitis	Viral infection, alcohol-associated disease, or autoimmune disease	Variable; ALT and AST may be more prominently elevated	Depends on the cause and injury pattern
Paget disease of bone	Disordered bone remodeling	May be markedly elevated, sometimes above 1,000 U/L; not required for diagnosis	GGT, ALT, and AST can remain normal if no separate liver disorder is present
Other bone conditions	Bone tumors or metastases; healing fractures	Variable, depending on bone activity	GGT, ALT, and AST can remain normal
Growth	Pubertal growth spurts	Higher age-specific ranges; 500–800 U/L is not a universal normal range	A bone source need not raise GGT
Pregnancy	Additional enzyme production by the placenta, especially in the third trimester	Can increase physiologically	A placental source does not establish liver disease
Medications	Some antibiotics, antiseizure drugs, and rarely ACE inhibitors	Variable; a rise is not automatically temporary or harmless	Depends on the drug and mechanism

Source

Source

Source

Source

Source

Source

Source

Source

Source

Source

Working out whether ALP comes from the liver or bones

ALT (alanine aminotransferase) and AST (aspartate aminotransferase) provide context about possible liver-cell injury. They help interpret the overall pattern, but neither test by itself establishes where an elevated ALP comes from. AST can also rise for reasons outside the liver. Source

GGT is useful because bone does not contribute to circulating GGT. An accompanying GGT elevation supports a liver or bile-duct source, but GGT is not specific to one disease. Bilirubin adds information about bile handling; its level alone cannot prove or exclude a blocked bile duct. Source Source

Calcium and phosphorus provide additional clues about bone metabolism. Parathyroid hormone (PTH) and vitamin D help regulate bone turnover and can help narrow down the explanation for a bone-related ALP elevation. Which tests are useful depends on the clinical question. Source Source

An unexpected elevated ALP result is often repeated to confirm it. GGT can help assess whether the source is hepatic. If the origin remains unclear, an ALP isoenzyme test separates different forms of the enzyme to help distinguish liver, bone, or another tissue source. Repeat testing should not delay an assessment when symptoms or other findings suggest an urgent problem. Source Source

What alkaline phosphatase does

Alkaline phosphatase is a family of enzymes found in several tissues, including the liver, bones, kidneys, intestine, and placenta. These enzymes remove phosphate groups from molecules; bone ALP has an important role in mineralization. Increased production or release from affected tissues can raise activity measured in the blood. ALP is not simply a protein-digesting enzyme. Source Source Source

Liver and bone are the main contributors to circulating ALP in most adults. Liver ALP is associated with the bile canalicular membranes, while bone ALP reflects the activity of bone-forming cells. Growth and fracture repair can increase the bone contribution. These different sources explain why a high result may accompany either a liver or a bone condition; it does not mean ALP itself digests dietary fat. Source Source

The enzyme gets its name from its greater activity under alkaline, or basic, laboratory conditions. That property helps laboratories measure it. Its diagnostic usefulness comes from its tissue sources and the pattern of results, rather than from an ability to reveal every condition that other tests miss. Source Source

What is a normal ALP level?

An adult reference interval sometimes quoted is 44–147 U/L, but laboratories use different methods and ranges. Interpret your result against the interval printed on your report. Reference intervals commonly describe the middle 95% of a reference population; they are not universal targets for an ‘optimal’ result or a reason to push ALP as low as possible. Source Source Source

Age, sex, growth, and pregnancy affect interpretation. Children and adolescents generally need different reference ranges from adults. Bone turnover can also change later in life, including after menopause. A result should not automatically be dismissed as normal aging merely because someone is over 65. Source

Previous results can help. For example, a change from about 60 to 120 U/L may merit attention in the right clinical context even if both values fall within the laboratory range. It does not automatically signal disease or require the same investigation for everyone. Symptoms, medications, measurement variation, and the longer-term trend all matter. Source

A low ALP result has a different set of possible explanations and needs its own interpretation.

How ALP is tested

A blood sample is taken from a vein, usually into a tube suitable for serum testing. Automated laboratory instruments measure the enzyme’s activity by tracking how quickly it acts on a test substrate. The result describes activity per unit of blood, not a direct measurement of damage to a particular organ. Source

Follow the preparation instructions from the clinic or laboratory. Fasting may be requested, particularly if other blood tests are being collected at the same time. In people with certain blood-group and secretor characteristics, intestinal ALP can rise after eating. Consistent sampling conditions can help when comparing results, but the cited study does not establish that every ALP test must be taken in the morning. Source

What can change alkaline phosphatase?

Alcohol-associated liver disease can alter liver tests, but ALP is not a reliable stand-alone measure of recent alcohol intake. The cited guideline does not establish that moderate drinking predictably causes a temporary ALP rise. Weight changes and their accompanying health changes may also matter. The cited weight-related study examined people after bariatric surgery; it should not be generalized to every episode of weight gain or loss. Source Source

Exercise and bone remodeling are related, and research has examined biochemical responses to resistance and endurance training. These studies do not establish a predictable rise in total ALP after every workout or show that an elevated result is harmless. Total ALP, bone-specific markers, and liver enzymes measure different processes. Tell your clinician about recent strenuous exercise so it can be considered alongside the other findings. Source Source

Stress and sleep are relevant to overall health, and proposed links between psychological stress and bone metabolism are being studied. The cited review discusses possible mechanisms, including hormonal pathways; it is not evidence that poor sleep explains an individual’s elevated ALP or that improving sleep will normalize it. These possibilities should not replace an assessment for established liver or bone causes. Source

When an ALP test can help

ALP can provide clues to liver or bone disease before symptoms appear. When a relevant condition has been identified, serial measurements may help track treatment or detect possible medication-related injury. Other liver tests, bone-related measurements, and sometimes imaging help determine the source. Its value depends on the clinical setting; a normal result does not rule out every liver or bone disorder. Source Source

Frequently asked questions

Should I worry if my alkaline phosphatase is high?

An elevated result deserves interpretation, but it does not automatically mean a serious illness. Liver or bile-duct disease, bone conditions, pregnancy, growth, and medications are among the possibilities. Medication-related elevations are not necessarily harmless. Your care team considers symptoms, medical history, other results, and the size and persistence of the change to decide what comes next. Source

How is high ALP treated?

Treatment addresses the cause rather than the number itself. A liver or bile-duct explanation may call for treatment of hepatitis, relief of an obstruction, or a clinician-directed medication change. Bone-related elevations may require treatment for Paget disease or another bone disorder. Do not stop prescribed medication on your own. The cited antibiotic study examined bile-canalicular effects in vitro; it is not a general treatment guideline. Source Source

How long does it take for ALP to fall?

There is no single timetable. In trials of zoledronic acid for Paget disease, the median time to a first therapeutic response was 64 days, roughly nine weeks. Response meant normalization of ALP or at least a 75% reduction in the ALP excess above the reference limit, not a 75% reduction in total ALP. That finding applies to that treatment and condition. Other causes may improve over weeks or months, and some remain persistently elevated. The cited azathioprine study does not establish that all liver-related elevations resolve faster than bone-related ones. Source Source

Which medications can raise alkaline phosphatase?

Some antibiotics, including erythromycin, and antiseizure medications such as phenytoin can be associated with an ALP rise through different mechanisms. ACE inhibitors can rarely cause liver injury. Estrogens and oral contraceptives can also cause cholestatic injury in susceptible people; this is not the same as a routine harmless temporary increase. The risk depends on the specific drug and clinical circumstances. Review all medicines and supplements with the care team rather than stopping a prescribed treatment yourself. Source

Can bone conditions cause high alkaline phosphatase?

Yes. Paget disease can produce substantial elevations, occasionally above 1,000 U/L, but neither that level nor any single threshold is required for the diagnosis. Bone tumors, some bone metastases, and healing fractures may also raise ALP through increased bone activity. A cancer-related elevation should not be described as merely temporary. GGT and, when needed, ALP isoenzyme testing help distinguish a bone contribution from a liver source. Source Source

Why can alkaline phosphatase be high in women?

Pregnancy can raise ALP, particularly in the third trimester, because the placenta produces additional enzyme. After delivery, the placental contribution usually recedes. Bone turnover can change after menopause. Hormone-containing medicines may occasionally be involved, but liver and bile-duct disease and other causes still need consideration. It is not valid to assume most elevations in women are hormonal or bone-related. GGT and other findings help clarify the source; the pregnancy paper cited here is a report of an extreme elevation, not a reference interval for all pregnancies. Source Source Source

Which other blood tests help identify the cause?

ALT and AST help characterize possible liver-cell injury. An elevated GGT alongside ALP supports a liver or bile-duct source; a normal GGT may make a bone source more likely but does not absolutely exclude liver disease. Bilirubin, calcium, phosphorus, vitamin D, and PTH can provide additional context. No single combination replaces consideration of symptoms, medical history, and, when appropriate, imaging or isoenzyme analysis. Source Source

Can low alkaline phosphatase signal a health problem?

Sometimes. A persistently low result should be interpreted against the age- and sex-appropriate laboratory range; below 40 IU/L is not a universal diagnostic cutoff. Possible explanations include nutritional deficiencies and hypothyroidism. Hypophosphatasia is a rare inherited condition associated with persistently low ALP and problems with bone or tooth mineralization. Chronic kidney disease can involve different patterns of bone turnover, so it does not uniformly lower ALP. Heart failure is not established here as a general cause of low ALP through a ‘slowed metabolism’; congestive liver injury can instead raise it. Source Source Source

References

Kwo PY, Cohen SM, Lim JK (2017). ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. The American journal of gastroenterology, 112(1), 18-35. https://doi.org/10.1038/ajg.2016.517 Publication

Ralston SH, Corral-Gudino L, Cooper C, Francis RM, Fraser WD, Gennari L, Guañabens N, Javaid MK, Layfield R, O’Neill TW, Russell RGG, Stone MD, Simpson K, Wilkinson D, Wills R, Zillikens MC, Tuck SP (2019). Diagnosis and Management of Paget’s Disease of Bone in Adults: A Clinical Guideline. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 34(4), 579-604. https://doi.org/10.1002/jbmr.3657 Publication

Ferianec V, Linhartová L (2011). Extreme elevation of placental alkaline phosphatase as a marker of preterm delivery, placental insufficiency and low birth weight. Neuro endocrinology letters, 32(2), 154-7. https://pubmed.ncbi.nlm.nih.gov/21552196/ Publication

Lowe D, Sanvictores T, Zubair M, John S (2026). Serum alkaline phosphatase: Clinical and laboratory perspectives. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459201/ Publication

Minisola S, Cipriani C, Colangelo L, Labbadia G, Pepe J, Magnusson P (2025). Diagnostic Approach to Abnormal Alkaline Phosphatase Value. Mayo Clinic proceedings, 100(4), 712-728. https://doi.org/10.1016/j.mayocp.2024.11.019 Publication

Sen AT, Derman O, Kinik E (2000). The relationship between osteocalcin levels and sexual stages of puberty in male children. The Turkish journal of pediatrics, 42(4), 281-5. https://pubmed.ncbi.nlm.nih.gov/11196743/ Publication

Ozarda Y (2016). Reference intervals: current status, recent developments and future considerations. Biochemia medica, 26(1), 5-16. https://doi.org/10.11613/BM.2016.001 Publication

Cejka D, Wakolbinger-Habel R, Zitt E, Fahrleitner-Pammer A, Amrein K, Dimai HP, Muschitz C (2023). [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)]. Wiener medizinische Wochenschrift (1946), 173(13-14), 299-318. https://doi.org/10.1007/s10354-022-00989-0 Publication

Greenblatt MB, Tsai JN, Wein MN (2017). Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease. Clinical chemistry, 63(2), 464-474. https://doi.org/10.1373/clinchem.2016.259085 Publication

Uemura H, Uemura H, Matsubara N, Kinuya S, Hosono M, Yajima Y, Doi T (2017). Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases. International journal of clinical oncology, 22(5), 954-963. https://doi.org/10.1007/s10147-017-1130-1 Publication

Sharanek A, Burban A, Ciriaci N, Guillouzo A (2019). Pro-inflammatory cytokines enhance dilatation of bile canaliculi caused by cholestatic antibiotics. Toxicology in vitro : an international journal published in association with BIBRA, 58, 51-59. https://doi.org/10.1016/j.tiv.2019.03.015 Publication

Barbiturates (2021). In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.ncbi.nlm.nih.gov/books/NBK548260/ Publication

Angiotensin-converting enzyme inhibitors (2018). In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.ncbi.nlm.nih.gov/books/NBK548912/ Publication

Dahir KM, Nunes ME (2007). Hypophosphatasia. In GeneReviews. University of Washington, Seattle. https://www.ncbi.nlm.nih.gov/books/NBK1150/ Publication

Wu JF, Jha P, Doucette S, Abid H (2022). Significantly Elevated Alkaline Phosphatase Caused by Congestive Hepatopathy in the Setting of Heart Failure with Preserved Ejection Fraction. WMJ : official publication of the State Medical Society of Wisconsin, 121(1), E14-E17. https://pubmed.ncbi.nlm.nih.gov/35442588/ Publication

Matsushita M, Harajiri S, Tabata S, Yukimasa N, Muramoto Y, Komoda T (2013). [Alkaline phosphatase activity in blood group B or O secretors is fluctuated by the dinner intake of previous night]. Rinsho byori. The Japanese journal of clinical pathology, 61(4), 307-12. https://pubmed.ncbi.nlm.nih.gov/23855186/ Publication

Ciecko C, Okut H, Lancaster B, Schwasinger-Schmidt T (2023). Prevalence of elevated alkaline phosphatase levels among post-bariatric surgery patients. Langenbeck’s archives of surgery, 408(1), 285. https://doi.org/10.1007/s00423-023-03021-0 Publication

Honda A, Kon M, Matsubayashi T, Suzuki Y (2020). Short-Term Intermittent Hypoxic Resistance Training Does Not Impair Osteogenic Response in Sea Level Residents. High altitude medicine & biology, 21(2), 160-166. https://doi.org/10.1089/ham.2019.0089 Publication

Niemelä M, Kangastupa P, Niemelä O, Bloigu R, Juvonen T (2016). Individual responses in biomarkers of health after marathon and half-marathon running: is age a factor in troponin changes?. Scandinavian journal of clinical and laboratory investigation, 76(7), 575-580. https://doi.org/10.1080/00365513.2016.1225122 Publication

Ng JS, Chin KY (2021). Potential mechanisms linking psychological stress to bone health. International journal of medical sciences, 18(3), 604-614. https://doi.org/10.7150/ijms.50680 Publication

Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M (2019). Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.), 69(1), 394-419. https://doi.org/10.1002/hep.30145 Publication

Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005). Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. The New England journal of medicine, 353(9), 898-908. https://doi.org/10.1056/NEJMoa044241 Publication

Siramolpiwat S, Sakonlaya D (2017). Clinical and histologic features of Azathioprine-induced hepatotoxicity. Scandinavian journal of gastroenterology, 52(8), 876-880. https://doi.org/10.1080/00365521.2017.1311936 Publication

Estrogens and oral contraceptives (2020). In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.ncbi.nlm.nih.gov/books/NBK548539/ Publication